Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 810 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

RJV001 Study in Adults Receiving Abdominoplasty

NCT04821648
Conditions
Submental Fat (SMF), Double Chin
Interventions
RJV001, Placebo
Drug
Lead sponsor
Rejuven Dermaceutical Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT04491877
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSV vaccine formulation 1, RSV vaccine formulation 2, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 18 Months
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
25
States / cities
Gardena, California • La Mesa, California • Los Angeles, California + 21 more
Conditions
Gut Health
Interventions
Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Conditions
Anti-biotic Resistance
Interventions
VSL#3, sugar pill (placebo)
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidate, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
25
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 22 more
Completed Phase 1 Interventional Accepts healthy volunteers

Bowman-Birk Inhibitor Concentrate in Healthy Men

NCT00679094
Conditions
Healthy, no Evidence of Disease
Interventions
Bowman-Birk inhibitor concentrate, placebo, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pediculus Humanus Capitis, Head Lice
Interventions
Placebo, BGC20-0582
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Florida City, Florida
Conditions
Laryngopharyngeal Reflux
Interventions
Fosamprenavir Calcium, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 64 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
Conditions
Constipation - Functional
Interventions
CDD-2101
Drug
Lead sponsor
Centre for Chinese Herbal Medicine Drug Development Limited
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Angelman Syndrome
Interventions
Nutritional Formulation Containing Exogenous Ketones, Placebo Formulation
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
4 Years to 11 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Completed Phase 4 Interventional Results available

Adalimumab in JIA-associated Uveitis Stopping Trial

NCT03816397
Conditions
Uveitis, JIA
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Conditions
Healthy
Interventions
PF-06650833, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Postoperative Pain, IVF
Interventions
acetaminophen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York